Immune Thrombocytopenia: Incidence, Diagnosis, Presentation, and Surgical Management

  • Kenneth John Bogenberger
  • Chan W. Park


Immune thrombocytopenia (ITP), previously referred to in literature and practice as idiopathic thrombocytopenia purpura, is an acquired disorder of immune-mediated destruction of platelets. In the acute setting, the principal goals of treatment are to prevent or stop life-threatening hemorrhage, evaluate for secondary causes, and promptly initiate treatment while monitoring for adverse events. The treatment of chronic ITP has evolved over the last 20 years, and with new therapeutic targets, improving rates of remission with medical therapy alone is possible. Patients with chronic ITP require a multidisciplinary team whose job is to navigate important decisions with regard to treatment and management of the patient’s comorbidities and mitigate the risk of deleterious effects caused by many of these therapies. Surgery remains an important treatment modality in refractory cases.


Immune thrombocytopenia ITP Hematologic disorders Thrombocytopenia Splenectomy 


  1. 1.
    Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–520.PubMedCrossRefGoogle Scholar
  2. 2.
    Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–21.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu S-R, Kuo H-C, Huang W-C, et al. Incidence, clinical characteristics, and associated diseases in patients with immune thrombocytopenia: a nationwide population-based study in Taiwan. Thromb Res. 2018;164:90–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee JY, Lee J-H, Lee H, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb Res. 2017;155:86–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Khan AM, Mydra H, Nevarez A. Clinical practice updates in the management of immune thrombocytopenia. P T. 2017;42(12):756–63.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Dal MS, Karakus A, Dal T, et al. Assessment of the underlying causes of the immune thrombocytopenia: ten years experience. J Pak Med Assoc. 2017;67(7):1004–8.PubMedGoogle Scholar
  9. 9.
    Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007;44(4 Suppl 5):S24–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010;116(12):2127–33.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.PubMedCrossRefGoogle Scholar
  12. 12.
    Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother. 2013;9(5):1158–62.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–35.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Palau J, Jarque I, Sanz MA. Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med. 2010;3:305–11.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Kojouri K. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Katkhouda N, Grant SW, Mavor E, et al. Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura. Surg Endosc. 2001;15(5):484–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4):E267–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim DK, Riley LE, Hunter P, on behalf of the Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older, United States, 2018*. Ann Intern Med. 2018;168(3):210.PubMedCrossRefGoogle Scholar
  19. 19.
    Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875–87.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Chater C, Terriou L, Duhamel A, et al. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016;264(5):772–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Morris KT, Horvath KD, Jobe BA, Swanstrom LL. Laparoscopic management of accessory spleens in immune thrombocytopenic purpura. Surg Endosc. 1999;13(5):520–2.PubMedCrossRefGoogle Scholar
  22. 22.
    Gigot J-F, Gigot F, Jamar F, et al. Inadequate detection of accessory spleens and splenosis with laparoscopic splenectomy A shortcoming of the laparoscopic approach in hematologic diseases. Surg Endosc. 1998;12(2):101–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Moris D, Dimitriou N, Griniatsos J. Laparoscopic splenectomy for benign hematological disorders in adults: a systematic review. In Vivo. 2017;31(3):291–302.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Rattner DW, Ellman L, Warshaw AL. Portal vein thrombosis after elective splenectomy. An underappreciated, potentially lethal syndrome. Arch Surg. 1993;128(5):565–569; discussion 569-570.PubMedCrossRefGoogle Scholar
  25. 25.
    Rottenstreich A, Kleinstern G, Spectre G, Da’as N, Ziv E, Kalish Y. Thromboembolic events following splenectomy: risk factors, prevention, management and outcomes. World J Surg. 2018;42(3):675–81.PubMedCrossRefGoogle Scholar
  26. 26.
    de’Angelis N, Abdalla S, Lizzi V, et al. Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy. Surgery. 2017;162(6):1219–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Bouvier A, Gout M, Audia S, Chalumeau C, Rat P, Deballon O. Routine screening of splenic or portal vein thrombosis after splenectomy. Rev Med Interne. 2017;38(1):3–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Tran T, Demyttenaere SV, Polyhronopoulos G, et al. Recommended timing for surveillance ultrasonography to diagnose portal splenic vein thrombosis after laparoscopic splenectomy. Surg Endosc. 2010;24(7):1670–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection--an update. Crit Care Med. 1999;27(4):836–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90(1):72–7.PubMedGoogle Scholar
  31. 31.
    Chang CC, Chang HC, Wu CH, Chang CY, Liao CC, Chen TL. Adverse postoperative outcomes in surgical patients with immune thrombocytopenia. Br J Surg. 2013;100(5):684–692; discussion 693.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kenneth John Bogenberger
    • 1
  • Chan W. Park
    • 2
  1. 1.Department of General SurgeryTripler Army Medical CenterHonoluluUSA
  2. 2.Department of Surgery, Section of Bariatrics and Minimally Invasive SurgeryTripler Army Medical CenterHonoluluUSA

Personalised recommendations